



## Venous thromboembolism prevention in lower limb trauma – Can we do better?

|                               |   |
|-------------------------------|---|
| Journal:                      | <i>Phlebology</i>   |
| Manuscript ID                 | PHLEB-18-121  |
| Manuscript Type:              | Editorial   |
| Date Submitted by the Author: | 23-Aug-2018   |
| Complete List of Authors:     | Langridge, Benjamin; Imperial College London Department of Surgery and Cancer, Academic Section of Vascular Surgery<br>Goodall, Richard; Imperial College London Department of Surgery and Cancer, Academic Section of Vascular Surgery<br>Onida, Sarah; Imperial College London Department of Surgery and Cancer, Academic Section of Vascular Surgery<br>Shalhoub, Joseph; Imperial College London Department of Surgery and Cancer, Academic Section of Vascular Surgery<br>Davies, Alun; Imperial College London Department of Surgery and Cancer, Academic Section of Vascular Surgery |
| Revised Keywords:             | Deep vein thrombosis, Venous thromboembolism, VTE prophylaxis, Pulmonary embolism, Surgery  |
|                               |   |

1  
2  
3 **Venous thromboembolism prevention in lower limb trauma –**  
4 **Can we do better?**  
5  
6  
7

8 Langridge BJ<sup>1</sup>, Goodall RJ<sup>1</sup>, Onida S<sup>1</sup>, Shalhoub J<sup>1</sup>, Davies AH<sup>1</sup>  
9

- 10  
11  
12  
13 1. Academic Section of Vascular Surgery, Department of Surgery and Cancer, Imperial  
14 College London, UK.  
15  
16

17  
18  
19 Corresponding author: Professor Alun H Davies  
20

21 Email: a.h.davies@imperial.ac.uk  
22  
23

24  
25  
26 **Departmental address:** Academic Section of Vascular Surgery, Department of Surgery and  
27 Cancer, Imperial College London, 4<sup>th</sup> Floor, Charing Cross Hospital, Fulham Palace Road,  
28 London, W6 8RF, UK  
29  
30

31  
32  
33 Tel: +44 (0) 20 3311 7309  
34  
35

36  
37 **Conflict of interest**  
38

39 The Authors declare that there is no conflict of interest.  
40  
41

42  
43 **Funding**  
44

45 Not applicable  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3  
4 Trauma is one of the principal causes of death in young people. Each year approximately five  
5  
6 million people die as a result of trauma worldwide, responsible for a loss of more than 100  
7  
8 million disability-adjusted life years, a greater loss than that due to all malignant neoplasms  
9  
10 combined <sup>1</sup>. In patients who survive beyond the first day, venous thromboembolism (VTE) is  
11  
12 a leading cause of preventable mortality <sup>2</sup>. Trauma patients with lower limb fracture are at  
13  
14 especially high risk; fracture of the femur or tibia is an independent risk factor for DVT (odds  
15  
16 ratio [OR], 4.82; 95% confidence interval [CI], 2.79-8.33) <sup>3</sup>. The incidence of pulmonary  
17  
18 embolism (PE) is estimated at between 1.5% and 20%, while the incidence of deep vein  
19  
20 thrombosis (DVT) is estimated at between 11.8% and 65% <sup>4</sup>. Although the risk of VTE is  
21  
22 clearly heterogeneously distributed amongst the trauma population, these patients are often  
23  
24 also at an increased risk of bleeding, with accompanying concerns relating to the use of  
25  
26 pharmacological thromboprophylaxis. Additionally, mechanical compression can often be  
27  
28 contraindicated in the context of lower limb trauma. These considerations make the optimal  
29  
30 method of preventing VTE in this population an important and challenging issue.  
31  
32  
33  
34  
35  
36  
37

38 The heterogeneous distribution of VTE risk in lower limb trauma is due to a combination of  
39  
40 patient-related and injury-related factors. Trauma itself results in a systemic pro-  
41  
42 inflammatory and pro-thrombotic state; associated comorbidities, prolonged immobilisation,  
43  
44 concomitant spinal or head trauma, and surgical repair of venous injury all contribute and  
45  
46 fundamentally exert a pro-thrombotic effect via all arms of Virchow's eponymous triad.  
47  
48  
49

50 Whilst the risk of VTE is high, there are also concerns about the risk of bleeding in these  
51  
52 patients, and the use of pharmacological prophylaxis has been demonstrated to significantly  
53  
54 increase bleeding risk (RR 2.04; 95% CI 1.08 to 3.86) <sup>4</sup>. In trials that distinguish between  
55  
56  
57  
58  
59  
60

1  
2  
3 major and minor bleeding, current evidence only supports an increased risk of minor (RR  
4 2.37; 95% CI 1.13 to 4.98) rather than major (RR 1.03; 95% CI 0.26 to 4.06) bleeding; major  
5 bleeding being defined as “use of transfusion or any procedure to control bleeding”<sup>4</sup>. Whilst  
6  
7 it is well known that trauma patients are at high risk of bleeding, research has predominantly  
8  
9 focused on the point of presentation and probability of requiring massive transfusion.  
10  
11 Absolute risk and risk factors for delayed bleeding – that which occurs during admission and  
12  
13 thus central to thromboprophylaxis decisions – have not been well investigated and thus  
14  
15 make weighing the risks and benefits of prescribing anticoagulation extremely challenging.  
16  
17  
18  
19  
20  
21  
22

23 The National Institute for Health and Care Excellence (NICE) recommends the use of  
24  
25 pharmacological prophylaxis in trauma patients where the risk of VTE outweighs the risk of  
26  
27 bleeding<sup>5</sup>. Pharmacological prophylaxis is well established in reducing the risk of VTE,  
28  
29 being superior to mechanical prophylaxis alone in preventing DVT (RR 0.48; 95% CI 0.25 to  
30  
31 0.95) and with LMWH being more effective than unfractionated heparins (UH) (RR 0.68;  
32  
33 95% CI 0.50 to 0.94)<sup>4</sup>. The challenge when using these agents, therefore, relates to the  
34  
35 individual patient thrombotic and bleeding risk assessment.  
36  
37  
38  
39  
40  
41

42 Mechanical prophylaxis, such as graduated compression and intermittent pneumatic  
43  
44 compression, are established in their ability to reduce the risk of DVT when used alone in  
45  
46 trauma patients (RR 0.55; 95% CI 0.34 to 0.90)<sup>4</sup>, and to have a superior effect when  
47  
48 combined with pharmacological prophylaxis versus pharmacological prophylaxis alone (RR  
49  
50 0.34; 95% CI 0.19 to 0.60)<sup>4</sup>. However, these methods are contraindicated in lower extremity  
51  
52 trauma due to detrimental effects on wound and fracture healing in the damaged limb.  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 Inferior vena cava filters (IVCF) can be useful adjuncts in lower limb trauma where the risk  
4 of bleeding and extent of injury contraindicate both pharmacological and mechanical  
5 prophylaxis. IVCFs significantly reduce the risk of PE (OR 0.028,  $P < 0.001$ )<sup>6</sup>, however,  
6  
7 insertion is invasive, they do not prevent DVT and their impact on mortality is debated.  
8  
9  
10  
11  
12 IVCFs can have numerous complications including caval wall penetration or thrombosis, and  
13  
14 the frequency of complications increase with filter dwell time. The use of retrievable filters  
15  
16 has grown dramatically, however multiple studies have reported that the majority of IVCFs  
17  
18 are not being removed, often due to patients being lost to follow up<sup>7</sup>.  
19  
20  
21  
22

23 A method for VTE prophylaxis which has seen a re-emergence of interest is the use of  
24 neuromuscular electrical stimulation (NMES). The evidence base for NMES devices is  
25  
26 limited; they have been shown to increase venous blood flow in the leg, and to significantly  
27  
28 reduce the risk of DVT when compared to no thromboprophylaxis (meta-analysis of 717  
29  
30 patients; OR 0.29, 95% CI 0.13 to 0.65)<sup>8</sup>. However, compared to current practice, their  
31  
32 efficacy is less convincing; a recent Cochrane review found no clear benefit of NMES in the  
33  
34 prevention of VTE, with the quality of evidence described as low. There was no difference in  
35  
36 the total number of VTE events in the NMES group compared to graduated or intermittent  
37  
38 pneumatic compression. Compared to heparin, the risk of DVT was higher in the NMES  
39  
40 group (194 patients, OR 2.78, 95% CI 1.19 to 6.48), although it should be noted that these  
41  
42 studies were in perioperative rather than trauma patients<sup>9</sup>. NICE recognised the limited  
43  
44 evidence; nonetheless, it approved the use of the geko<sup>TM</sup> NMES devices for high risk VTE  
45  
46 patients where other forms of prophylaxis are contraindicated or unsuitable<sup>10</sup>. This may  
47  
48  
49  
50  
51  
52  
53 make NMES devices suitable in lower limb trauma; however there is limited evidence of  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 their use in this patient population and the practicalities of employing such a device in  
4  
5 traumatic limb injury are yet to be explored.  
6  
7

8  
9 Venous thromboembolism is an important cause of morbidity and mortality following lower  
10  
11 limb trauma, yet it is challenging to prevent in this patient population due to the complex  
12  
13 interplay of VTE and bleeding risk factors alongside mechanical considerations relating to  
14  
15 the traumatised limb. Further high quality studies are needed to explore several key areas,  
16  
17 including predictive factors for delayed haemorrhage, risk thresholds that should  
18  
19 contraindicate anticoagulation, and to validate alternative thromboprophylactic methods such  
20  
21 as NMES in this specific patient population.  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

**References**

1. World Health Organization. The Global Burden of Disease: 2004 update. 2008; 146.
2. Acosta JA, Yang JC, Winchell RJ, et al. Lethal Injuries and Time to Death in a Level I Trauma Center. *J Am Coll Surg* 1998; 186: 528–533.
3. Geerts WH, Code KI, Jay RM, et al. A Prospective Study of Venous Thromboembolism after Major Trauma. *N Engl J Med* 1994; 331: 1601–1606.
4. Barrera LM, Perel P, Ker K, et al. Thromboprophylaxis for trauma patients. *Cochrane Database Syst Rev*. Epub ahead of print 28 March 2013. DOI: 10.1002/14651858.CD008303.pub2.
5. The National Institute for Health and Clinical Excellence. Venous thromboembolism in over 16s: reducing the risk of hospital-acquired deep vein thrombosis or pulmonary embolism NG89, <https://www.nice.org.uk/guidance/ng89/chapter/Recommendations#risk-assessment> (2018, accessed 13 August 2018).
6. Han B, Ge C, Zhang H, et al. Prevention of pulmonary embolisms associated with vena cava filter implantation. *Phlebol J Venous Dis* 2015; 30: 24–31.
7. Tao MJ, Montbriand JM, Eisenberg N, et al. Temporary inferior vena cava filter indications, retrieval rates, and follow-up management at a multicenter tertiary care institution. *J Vasc Surg* 2016; 64: 430–437.
8. Ravikumar R, Williams KJ, Babber A, et al. Neuromuscular electrical stimulation for the prevention of venous thromboembolism. *Phlebol J Venous Dis* 2018; 33: 367–378.
9. Hajibandeh S, Hajibandeh S, Antoniou GA, et al. Neuromuscular electrical stimulation for the prevention of venous thromboembolism. *Cochrane Database Syst Rev*. Epub ahead of print 21 November 2017. DOI: 10.1002/14651858.CD011764.pub2.
10. The National Institute for Health and Clinical Excellence. The geko device for reducing the risk of venous thromboembolism. *Medical technologies guidance [MTG19]*, <https://www.nice.org.uk/guidance/mtg19> (2014, accessed 13 August 2018).

1  
2  
3  
4 Editor-in-Chief,  
5 PHLEBOLOGY  
6 16<sup>th</sup> August 2018  
7  
8

9 **Re: Disclosure of conflict of interest**  
10

11  
12 Dear Editor,  
13

14 I would like to make the following declarations regarding my submission to your journal on  
15 behalf of myself and my co-authors:  
16

17  
18 **Conflicting interests**

19 None of the authors have any conflicts of interest to declare.  
20

21 **Funding**

22 No funding was received for the preparation of this manuscript.  
23

24 **Ethical approval**

25 No ethical approval was required for the preparation of this manuscript.  
26

27 **Guarantor: AHD**  
28

29  
30 **Contributorship**

31 All listed authors have contributed to this manuscript in a substantive and meaningful  
32 manner. BL, RG, SO, JS and AHD conceived the manuscript. BL performed the initial  
33 literature search and first draft of the manuscript. All authors were involved in the subsequent  
34 redraft of the manuscript. All authors reviewed and edited the manuscript and approved the  
35 final version of the manuscript.  
36

37 **Acknowledgements**

38 There are no other individuals that have contributed to the preparation of this manuscript.  
39  
40

41 Thank you for considering our manuscript.  
42  
43

44  
45 Yours Sincerely,  
46 Dr Benjamin Langridge  
47

48 Academic Foundation Doctor  
49 Academic Section of Vascular Surgery,  
50 Department of Surgery and Cancer,  
51 Imperial College London, UK.  
52  
53  
54  
55  
56  
57  
58  
59  
60